N Peltz-Sinvani1,2, R Klempfner3,2, E Ramaty1,2, B A Sela4,2, I Goldenberg3,2, G Segal5,6. 1. Department of Internal Medicine "T", Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. 2. Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel. 3. Leviev Heart Institute, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. 4. Institute of Chemical Pathology, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. 5. Department of Internal Medicine "T", Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel. gad.segal@sheba.health.gov.il. 6. Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel. gad.segal@sheba.health.gov.il.
Abstract
BACKGROUND: Low alanine aminotransferase (ALT) blood levels are known to be associated with frailty and increased risk of long-term mortality in certain populations. However, the contribution of this marker to long-term outcome has not been assessed in patients with chronic coronary heart disease. OBJECTIVE: The aim of the current study was to assess the association between low ALT values and long-term, 22.8-year, all-cause mortality in this population. PARTICIPANTS: We examined the association of low ALT (<17 IU/l) with long-term all-cause mortality in the Bezafibrate Infarction Prevention (BIP) Registry population. KEY RESULTS: Appropriate laboratory and survival data were available for 6,575 patients, without known liver pathology, included in the BIP registry, with a median follow-up period of 22.8 years. The cumulative probability of all-cause mortality was significantly higher in the low ALT group compared with patients with higher ALT levels (65.6 % vs. 58.4 %; log-rank p < 0.001). Consistently, multivariate analysis, adjusted for multiple established predictors of mortality in this population, demonstrated that low ALT is independently associated with 11 % greater long-term (22.8 years) mortality risk [HR 1.11 (95 % confidence interval: 1.03-1.19; adjusted p < 0.01)]. CONCLUSIONS: Low ALT levels are associated with increased long-term mortality among middle-aged patients with stable coronary heart disease. This association remained statistically significant after adjustment for other well-established risk factors for mortality in this population.
BACKGROUND: Low alanine aminotransferase (ALT) blood levels are known to be associated with frailty and increased risk of long-term mortality in certain populations. However, the contribution of this marker to long-term outcome has not been assessed in patients with chronic coronary heart disease. OBJECTIVE: The aim of the current study was to assess the association between low ALT values and long-term, 22.8-year, all-cause mortality in this population. PARTICIPANTS: We examined the association of low ALT (<17 IU/l) with long-term all-cause mortality in the Bezafibrate Infarction Prevention (BIP) Registry population. KEY RESULTS: Appropriate laboratory and survival data were available for 6,575 patients, without known liver pathology, included in the BIP registry, with a median follow-up period of 22.8 years. The cumulative probability of all-cause mortality was significantly higher in the low ALT group compared with patients with higher ALT levels (65.6 % vs. 58.4 %; log-rank p < 0.001). Consistently, multivariate analysis, adjusted for multiple established predictors of mortality in this population, demonstrated that low ALT is independently associated with 11 % greater long-term (22.8 years) mortality risk [HR 1.11 (95 % confidence interval: 1.03-1.19; adjusted p < 0.01)]. CONCLUSIONS: Low ALT levels are associated with increased long-term mortality among middle-aged patients with stable coronary heart disease. This association remained statistically significant after adjustment for other well-established risk factors for mortality in this population.
Entities:
Keywords:
aging; cardiovascular disease; life course; risk assessment; screening; survey research
Authors: Juan Sanchis; Clara Bonanad; Vicente Ruiz; Julio Fernández; Sergio García-Blas; Luis Mainar; Silvia Ventura; Enrique Rodríguez-Borja; Francisco J Chorro; Carlos Hermenegildo; Vicente Bertomeu-González; Eduardo Núñez; Julio Núñez Journal: Am Heart J Date: 2014-07-30 Impact factor: 4.749
Authors: Roger K Schindhelm; Jacqueline M Dekker; Giel Nijpels; Lex M Bouter; Coen D A Stehouwer; Robert J Heine; Michaela Diamant Journal: Atherosclerosis Date: 2006-05-08 Impact factor: 5.162
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: David G Le Couteur; Fiona M Blyth; Helen M Creasey; David J Handelsman; Vasi Naganathan; Philip N Sambrook; Markus J Seibel; Louise M Waite; Robert G Cumming Journal: J Gerontol A Biol Sci Med Sci Date: 2010-05-24 Impact factor: 6.053
Authors: E Ramaty; E Maor; N Peltz-Sinvani; A Brom; A Grinfeld; S Kivity; S Segev; Y Sidi; T Kessler; B A Sela; G Segal Journal: Eur J Intern Med Date: 2014-10-30 Impact factor: 4.487
Authors: Kristine E Ensrud; Susan K Ewing; Brent C Taylor; Howard A Fink; Peggy M Cawthon; Katie L Stone; Teresa A Hillier; Jane A Cauley; Marc C Hochberg; Nicolas Rodondi; J Kathleen Tracy; Steven R Cummings Journal: Arch Intern Med Date: 2008-02-25
Authors: K Yasuda; K Okuda; N Endo; Y Ishiwatari; R Ikeda; H Hayashi; K Yokozeki; S Kobayashi; Y Irie Journal: Gastroenterology Date: 1995-10 Impact factor: 22.682
Authors: Silvia Muñoz; Lucía Méndez; Gabriel Dasilva; Josep Lluís Torres; Sara Ramos-Romero; Marta Romeu; María Rosa Nogués; Isabel Medina Journal: Mar Drugs Date: 2018-09-26 Impact factor: 5.118
Authors: Michael J Haley; Claire S White; Daisy Roberts; Kelly O'Toole; Catriona J Cunningham; Jack Rivers-Auty; Conor O'Boyle; Conor Lane; Oliver Heaney; Stuart M Allan; Catherine B Lawrence Journal: Transl Stroke Res Date: 2019-12-21 Impact factor: 6.829
Authors: N Lasman; M Shalom; N Turpashvili; G Goldhaber; Y Lifshitz; E Leibowitz; G Berger; G Saltzman-Shenhav; A Brom; D Cohen; C Avaky; G Segal Journal: BMC Pulm Med Date: 2020-05-11 Impact factor: 3.317
Authors: Michael Kogan; Robert Klempfner; Dor Lotan; Yishay Wasserstrum; Ilan Goldenberg; Gad Segal Journal: J Exerc Sci Fit Date: 2017-11-29 Impact factor: 3.103